Tenax Therapeutics Inc. (TENX)
TENX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/0001193125-26-099393-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TENX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000034956 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$52.6M |
| Operating income | -$56.4M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $97.6M |
| Total assets | $104.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $113.7M cash; operating cash flow -$12.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 45,536,448 (2026-10-31); 6,243,575 a year earlier; 23,862,434 three years earlier. 3y figure adjusted for splits (1-for-80 overall). | Cover page 2026-10-31 |
| Reverse splits, 3 years | 1; latest 1-for-80 on 2024-01-03 | Source 2024-01-03 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-24 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Cherry Bekaert LLP, Raleigh, North Carolina, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $5.1M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$16.7M | -$12.5M | $113.7M | No debt tags | $0 | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $0 | -$17.8M | -$14.2M | $118.0M | No debt tags | $0 | 10-Q 2026-07-31 |
| Q1 2026 2026-03-31 | $0 | -$15.7M | -$9.3M | $118.8M | No debt tags | $0 | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $0 | -$15.5M | -$13.4M | $97.6M | No debt tags | $0 | 10-K 2026-03-10 |
| Q3 2025 2025-09-30 | $0 | -$15.8M | -$9.2M | $99.4M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $0 | -$10.8M | -$6.3M | $105.5M | No debt tags | Needs four quarters | 10-Q 2025-08-13 |
| Q1 2025 2025-03-31 | $0 | -$10.4M | -$7.0M | $111.4M | No debt tags | Needs four quarters | 10-Q 2025-05-14 |
| Q4 2024 2024-12-31 | Not filed | -$6.3M | -$3.5M | $94.9M | $0 | $0 | 10-K 2026-03-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2026-03-24 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.1% |
| 1 month | +1.2% |
| 3 months | -11.5% |
| Year to date | -86.7% |
| 1 year | -75.8% |
| From 52-week high | -91.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GOSS | Gossamer Bio Inc. | $10.98 | +0.09% | $67.2M |
| ZYBT | Zhengye Biotechnology Holding Limited | $1.43 | -4.67% | $67.8M |
| MNOV | Medicinova Inc | $1.34 | -3.94% | $68.7M |
| CRBP | Corbus Pharmaceuticals Holdings Inc. | $3.38 | -0.44% | $69.5M |
| COYA | Coya Therapeutics Inc. | $3.00 | -4.15% | $70.4M |
| VTVT | vTv Therapeutics Inc. | $17.69 | -10.16% | $71.0M |
| ACRV | Acrivon Therapeutics Inc. | $1.46 | +0.69% | $62.6M |
| MAIA | MAIA Biotechnology Inc. | $1.01 | +1.00% | $62.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier